{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T01:14:15Z","timestamp":1783473255639,"version":"3.55.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"vor","delay-in-days":68,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82303586"],"award-info":[{"award-number":["82303586"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82373220"],"award-info":[{"award-number":["82373220"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Immunol"],"DOI":"10.1186\/s12865-026-00840-w","type":"journal-article","created":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T01:54:41Z","timestamp":1777600481000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Peripheral immune signatures associated with invasive behavior in pituitary neuroendocrine tumor: a blood-based analysis"],"prefix":"10.1186","volume":"27","author":[{"given":"Hongyu","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liangliang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuanbiao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jialin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangye","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,1]]},"reference":[{"issue":"3","key":"840_CR1","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1111\/j.1365-2265.2009.03667.x","volume":"72","author":"A Fernandez","year":"2010","unstructured":"Fernandez A, Karavitaki N, Wass JA. Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clin Endocrinol (Oxf). 2010;72(3):377\u201382.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"840_CR2","doi-asserted-by":"crossref","unstructured":"Sharma A, Porter AB. Nonglial Central Nervous System Tumors. In: Flemming KD, editor. Mayo Clinic Neurology Board Review; 2015. p. 931\u201348.","DOI":"10.1093\/med\/9780197512166.003.0104"},{"issue":"5","key":"840_CR3","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1001\/jama.2016.19699","volume":"317","author":"ME Molitch","year":"2017","unstructured":"Molitch ME. Diagnosis and Treatment of Pituitary Adenomas: A Review. JAMA. 2017;317(5):516\u201324.","journal-title":"JAMA"},{"issue":"2","key":"840_CR4","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1159\/000371806","volume":"101","author":"E Chatzellis","year":"2015","unstructured":"Chatzellis E, Alexandraki KI, Androulakis II, Kaltsas G. Aggressive pituitary tumors. Neuroendocrinology. 2015;101(2):87\u2013104.","journal-title":"Neuroendocrinology"},{"issue":"7","key":"840_CR5","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/nrendo.2014.64","volume":"10","author":"A Di Ieva","year":"2014","unstructured":"Di Ieva A, Rotondo F, Syro LV, Cusimano MD, Kovacs K. Aggressive pituitary adenomas\u2013diagnosis and emerging treatments. Nat Rev Endocrinol. 2014;10(7):423\u201335.","journal-title":"Nat Rev Endocrinol"},{"issue":"1","key":"840_CR6","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1530\/EJE-17-0796","volume":"178","author":"G Raverot","year":"2018","unstructured":"Raverot G, Burman P, McCormack A, Heaney A, Petersenn S, Popovic V, et al. European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas. Eur J Endocrinol. 2018;178(1):G1\u201324.","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"840_CR7","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1007\/s12031-019-01318-8","volume":"68","author":"H Joshi","year":"2019","unstructured":"Joshi H, Vastrad B, Vastrad C. Identification of Important Invasion-Related Genes in Non-functional Pituitary Adenomas. J Mol Neurosci. 2019;68(4):565\u201389.","journal-title":"J Mol Neurosci"},{"issue":"2","key":"840_CR8","first-page":"533","volume":"42","author":"Z Wang","year":"2019","unstructured":"Wang Z, Gao L, Guo X, Feng C, Deng K, Lian W, et al. Identification of microRNAs associated with the aggressiveness of prolactin pituitary tumors using bioinformatic analysis. Oncol Rep. 2019;42(2):533\u201348.","journal-title":"Oncol Rep"},{"issue":"27","key":"840_CR9","doi-asserted-by":"publisher","first-page":"5381","DOI":"10.1038\/s41388-019-0779-5","volume":"38","author":"S Barry","year":"2019","unstructured":"Barry S, Carlsen E, Marques P, Stiles CE, Gadaleta E, Berney DM, et al. Tumor microenvironment defines the invasive phenotype of AIP-mutation-positive pituitary tumors. Oncogene. 2019;38(27):5381\u201395.","journal-title":"Oncogene"},{"key":"840_CR10","doi-asserted-by":"crossref","unstructured":"Principe M, Chanal M, Ilie MD, Ziverec A, Vasiljevic A, Jouanneau E et al. Immune Landscape of Pituitary Tumors Reveals Association Between Macrophages and Gonadotroph Tumor Invasion. J Clin Endocrinol Metab. 2020;105(11):dgaa520.","DOI":"10.1210\/clinem\/dgaa520"},{"key":"840_CR11","doi-asserted-by":"publisher","first-page":"205873842110565","DOI":"10.1177\/20587384211056505","volume":"35","author":"S Shen","year":"2021","unstructured":"Shen S, Wu Q, Liu J, Wu L, Zhang R, Uemura Y, et al. Analysis of human glioma-associated co-inhibitory immune checkpoints in glioma microenvironment and peripheral blood. Int J Immunopathol Pharmacol. 2021;35:20587384211056505.","journal-title":"Int J Immunopathol Pharmacol"},{"key":"840_CR12","doi-asserted-by":"publisher","first-page":"665147","DOI":"10.3389\/fimmu.2021.665147","volume":"12","author":"L Wu","year":"2021","unstructured":"Wu L, Xie S, Wang L, Li J, Han L, Qin B, et al. The Ratio of IP10 to IL-8 in Plasma Reflects and Predicts the Response of Patients With Lung Cancer to Anti-PD-1 Immunotherapy Combined With Chemotherapy. Front Immunol. 2021;12:665147.","journal-title":"Front Immunol"},{"key":"840_CR13","doi-asserted-by":"publisher","first-page":"101775","DOI":"10.1016\/j.tranon.2023.101775","volume":"37","author":"L Wu","year":"2023","unstructured":"Wu L, Gao Y, Xie S, Ye W, Uemura Y, Zhang R, et al. The level of macrophage migration inhibitory factor is negatively correlated with the efficacy of PD-1 blockade immunotherapy combined with chemotherapy as a neoadjuvant therapy for esophageal squamous cell carcinoma. Transl Oncol. 2023;37:101775.","journal-title":"Transl Oncol"},{"issue":"6","key":"840_CR14","first-page":"9507","volume":"15","author":"L Wu","year":"2018","unstructured":"Wu L, Liu H, Guo H, Wu Q, Yu S, Qin Y, et al. Circulating and tumor-infiltrating myeloid-derived suppressor cells in cervical carcinoma patients. Oncol Lett. 2018;15(6):9507\u201315.","journal-title":"Oncol Lett"},{"key":"840_CR15","doi-asserted-by":"publisher","first-page":"598887","DOI":"10.3389\/pore.2021.598887","volume":"27","author":"X Huang","year":"2021","unstructured":"Huang X, Xu J, Wu Y, Sheng L, Li Y, Zha B, et al. Alterations in CD8(+) Tregs, CD56(+) Natural Killer Cells and IL-10 Are Associated With Invasiveness of Nonfunctioning Pituitary Adenomas (NFPAs). Pathol Oncol Res. 2021;27:598887.","journal-title":"Pathol Oncol Res"},{"issue":"1","key":"840_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S1074-7613(01)00261-8","volume":"16","author":"EJ Kunkel","year":"2002","unstructured":"Kunkel EJ, Butcher EC. Chemokines and the tissue-specific migration of lymphocytes. Immunity. 2002;16(1):1\u20134.","journal-title":"Immunity"},{"issue":"1","key":"840_CR17","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1186\/s40478-019-0830-3","volume":"7","author":"P Marques","year":"2019","unstructured":"Marques P, Barry S, Carlsen E, Collier D, Ronaldson A, Awad S, et al. Chemokines modulate the tumour microenvironment in pituitary neuroendocrine tumours. Acta Neuropathol Commun. 2019;7(1):172.","journal-title":"Acta Neuropathol Commun"},{"key":"840_CR18","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.canlet.2017.09.022","volume":"411","author":"H Liu","year":"2017","unstructured":"Liu H, Chen L, Liu J, Meng H, Zhang R, Ma L, et al. Co-delivery of tumor-derived exosomes with alpha-galactosylceramide on dendritic cell-based immunotherapy for glioblastoma. Cancer Lett. 2017;411:182\u201390.","journal-title":"Cancer Lett"},{"issue":"1","key":"840_CR19","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/s41577-020-0396-0","volume":"21","author":"P Angkasekwinai","year":"2021","unstructured":"Angkasekwinai P, Dong C. IL-9-producing T cells: potential players in allergy and cancer. Nat Rev Immunol. 2021;21(1):37\u201348.","journal-title":"Nat Rev Immunol"},{"key":"840_CR20","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/978-1-4939-6877-0_2","volume":"1585","author":"WG Rojas-Zuleta","year":"2017","unstructured":"Rojas-Zuleta WG, Sanchez E. IL-9: Function, Sources, and Detection. Methods Mol Biol. 2017;1585:21\u201335.","journal-title":"Methods Mol Biol"},{"key":"840_CR21","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/978-3-030-38315-2_3","volume":"1240","author":"Y He","year":"2020","unstructured":"He Y, Dong L, Cao Y, Bi Y, Liu G. IL-9 and Th9 Cells in Tumor Immunity. Adv Exp Med Biol. 2020;1240:35\u201346.","journal-title":"Adv Exp Med Biol"},{"issue":"1","key":"840_CR22","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s00281-016-0599-4","volume":"39","author":"T Rivera Vargas","year":"2017","unstructured":"Rivera Vargas T, Humblin E, V\u00e9gran F, Ghiringhelli F, Apetoh L. T(H)9 cells in anti-tumor immunity. Semin Immunopathol. 2017;39(1):39\u201346.","journal-title":"Semin Immunopathol"},{"issue":"5","key":"840_CR23","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.21873\/invivo.12066","volume":"34","author":"T Mickevicius","year":"2020","unstructured":"Mickevicius T, Vilkeviciute A, Glebauskiene B, Kriauciuniene L, Liutkeviciene R. Do TRIB1 and IL-9 Gene Polymorphisms Impact the Development and Manifestation of Pituitary Adenoma? Vivo. 2020;34(5):2499\u2013505.","journal-title":"Vivo"},{"key":"840_CR24","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/978-3-030-36667-4_3","volume":"1231","author":"N Mukaida","year":"2020","unstructured":"Mukaida N, Sasaki SI, Baba T. CCL4 Signaling in the Tumor Microenvironment. Adv Exp Med Biol. 2020;1231:23\u201332.","journal-title":"Adv Exp Med Biol"},{"key":"840_CR25","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1146\/annurev-immunol-032713-120145","volume":"32","author":"JW Griffith","year":"2014","unstructured":"Griffith JW, Sokol CL, Luster AD. Chemokines and chemokine receptors: positioning cells for host defense and immunity. Annu Rev Immunol. 2014;32:659\u2013702.","journal-title":"Annu Rev Immunol"},{"key":"840_CR26","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.3389\/fimmu.2018.02443","volume":"9","author":"J Salido","year":"2018","unstructured":"Salido J, Ruiz MJ, Trifone C, Figueroa MI, Caruso MP, Gherardi MM, et al. Phenotype, Polyfunctionality, and Antiviral Activity of in vitro Stimulated CD8(+) T-Cells From HIV(+) Subjects Who Initiated cART at Different Time-Points After Acute Infection. Front Immunol. 2018;9:2443.","journal-title":"Front Immunol"},{"issue":"2","key":"840_CR27","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1097\/00042560-200202010-00003","volume":"29","author":"M Pierdominici","year":"2002","unstructured":"Pierdominici M, Giovannetti A, Ensoli F, Mazzetta F, Marziali M, De Cristofaro MR, et al. Changes in CCR5 and CXCR4 expression and beta-chemokine production in HIV-1-infected patients treated with highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2002;29(2):122\u201331.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"2","key":"840_CR28","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1002\/path.3029","volume":"226","author":"FR Balkwill","year":"2012","unstructured":"Balkwill FR. The chemokine system and cancer. J Pathol. 2012;226(2):148\u201357.","journal-title":"J Pathol"},{"key":"840_CR29","doi-asserted-by":"crossref","unstructured":"Li B, Zhao S, Chen Y, Gao H, Xie W, Wang H et al. HSPB1 promotes tumor invasion by inducing angiogenesis in PitNETs. Endocr Relat Cancer. 2024;31(6):e230045.","DOI":"10.1530\/ERC-23-0045"},{"issue":"4","key":"840_CR30","first-page":"399","volume":"72","author":"O Yoshie","year":"2000","unstructured":"Yoshie O. Role of chemokines in trafficking of lymphocytes and dendritic cells. Int J Hematol. 2000;72(4):399\u2013407.","journal-title":"Int J Hematol"},{"issue":"2","key":"840_CR31","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1097\/00024382-200302000-00010","volume":"19","author":"CJ Godshall","year":"2003","unstructured":"Godshall CJ, Scott MJ, Burch PT, Peyton JC, Cheadle WG. Natural killer cells participate in bacterial clearance during septic peritonitis through interactions with macrophages. Shock. 2003;19(2):144\u20139.","journal-title":"Shock"},{"issue":"6448","key":"840_CR32","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1038\/365756a0","volume":"365","author":"J Bernhagen","year":"1993","unstructured":"Bernhagen J, Calandra T, Mitchell RA, Martin SB, Tracey KJ, Voelter W, et al. MIF is a pituitary-derived cytokine that potentiates lethal endotoxaemia. Nature. 1993;365(6448):756\u20139.","journal-title":"Nature"},{"issue":"10","key":"840_CR33","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1038\/nri1200","volume":"3","author":"T Calandra","year":"2003","unstructured":"Calandra T, Roger T. Macrophage migration inhibitory factor: a regulator of innate immunity. Nat Rev Immunol. 2003;3(10):791\u2013800.","journal-title":"Nat Rev Immunol"},{"issue":"3","key":"840_CR34","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1002\/med.21385","volume":"36","author":"C O\u2019Reilly","year":"2016","unstructured":"O\u2019Reilly C, Doroudian M, Mawhinney L, Donnelly SC. Targeting MIF in Cancer: Therapeutic Strategies, Current Developments, and Future Opportunities. Med Res Rev. 2016;36(3):440\u201360.","journal-title":"Med Res Rev"},{"issue":"1","key":"840_CR35","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1677\/joe.0.1760103","volume":"176","author":"ME Pyle","year":"2003","unstructured":"Pyle ME, Korbonits M, Gueorguiev M, Jordan S, Kola B, Morris DG, et al. Macrophage migration inhibitory factor expression is increased in pituitary adenoma cell nuclei. J Endocrinol. 2003;176(1):103\u201310.","journal-title":"J Endocrinol"},{"issue":"3","key":"840_CR36","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1182\/blood-2011-04-325225","volume":"119","author":"BB Aggarwal","year":"2012","unstructured":"Aggarwal BB, Gupta SC, Kim JH. Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey. Blood. 2012;119(3):651\u201365.","journal-title":"Blood"},{"issue":"1\u20132","key":"840_CR37","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1385\/IR:35:1:41","volume":"35","author":"DD McCarthy","year":"2006","unstructured":"McCarthy DD, Summers-Deluca L, Vu F, Chiu S, Gao Y, Gommerman JL. The lymphotoxin pathway: beyond lymph node development. Immunol Res. 2006;35(1\u20132):41\u201354.","journal-title":"Immunol Res"},{"issue":"5","key":"840_CR38","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1159\/000341690","volume":"30","author":"J Bauer","year":"2012","unstructured":"Bauer J, Namineni S, Reisinger F, Z\u00f6ller J, Yuan D, Heikenw\u00e4lder M, Lymphotoxin. NF-\u0138B, and cancer: the dark side of cytokines. Dig Dis. 2012;30(5):453\u201368.","journal-title":"Dig Dis"},{"issue":"2","key":"840_CR39","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1046\/j.1365-2265.1996.d01-1554.x","volume":"45","author":"VL Green","year":"1996","unstructured":"Green VL, Atkin SL, Speirs V, Jeffreys RV, Landolt AM, Mathew B, et al. Cytokine expression in human anterior pituitary adenomas. Clin Endocrinol (Oxf). 1996;45(2):179\u201385.","journal-title":"Clin Endocrinol (Oxf)"}],"container-title":["BMC Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12865-026-00840-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12865-026-00840-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12865-026-00840-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:22:59Z","timestamp":1783470179000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12865-026-00840-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,1]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["840"],"URL":"https:\/\/doi.org\/10.1186\/s12865-026-00840-w","relation":{},"ISSN":["1471-2172"],"issn-type":[{"value":"1471-2172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,1]]},"assertion":[{"value":"10 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki. The research protocol was approved by the Medical Ethics Committee of the First Medical Center of Chinese PLA General Hospital (S2021-677-01). Written informed consent was obtained from all participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"53"}}